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Introduction 
 
 Yellow fever is a highly fatal, incurable viral infection. Not all who are bitten by an 
infected mosquito develop symptoms but many of those who do experience fever, headache, 
pain, nausea and dizziness over a period of three to six days at which point they recover and are 
thereafter fully immune. Less fortunate are those who develop the classic symptoms of yellow 
fever. Following a brief period of remission, the onset of classic yellow fever is signaled by the 
return of high fever together with nausea and vomiting. It is at this point that the more 
frightening symptoms of jaundice, kidney failure and hemorrhage appear, leading at times to the 
black vomit or vomito negro for which the condition was once known. As an incurable infection, 
physicians can do very little for people suffering from yellow fever and half of those who 
develop severe symptoms experience shock, seizures and become comatose before dying. This 
high mortality and lack of effective treatment make the return of yellow fever a fearful prospect 
and explain why it was once a terrifying disease. In the Americas, yellow fever was, for a period 
of several hundred years, an unrelenting source of epidemics causing significant loss of life and 
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endless commercial disruption. Efforts to eradicate yellow fever following the early 20
th
 century 
discovery of the mosquito vector and mass vaccination in endemic regions of South and Central 
America brought an effective end to “New World” epidemics. The same, however, cannot be 
said for Africa.  
 Since the middle of the 20
th
 century epidemic outbreaks have been confined almost 
exclusively to Africa, where 90 percent of all yellow fever incidence reportedly occurs. As 
yellow fever was originally from Africa, only crossing the Atlantic together with enslaved 
populations and one of yellow fever’s primary mosquito vectors, its ongoing impact in Africa 
might be seen as an inevitable feature of the African environment. Moreover, this view of Africa 
as inherently diseased has a long history and yellow fever played a significant role in the high 
European mortality that made West Africa the “white man’s grave.” A historical analysis of the 
ongoing public health threat of yellow fever in Africa is lacking and long overdue. This paper 
represents a preliminary examination of that history based solely on archives held at the 
Rockefeller Archive Center concerning the period from 1920 until the close of the Second World 
War. It provisionally argues that the high burden of yellow fever in Africa and especially the 
unequal burden of yellow fever from mid-century was far from inevitable. Instead, it represents a 
failure of colonial medicine and global health –albeit, hopefully, a temporary one.  
  
The Rockefeller Yellow Fever Commission and Immunity Surveys in Africa 
In 1920, on the heels of the apparent eradication of yellow fever from key urban and commercial 
centers in the Americas, the International Health Board of the Rockefeller Foundation sent a 
team to investigate yellow fever in West Africa. After finding that the disease was both endemic 
and epidemic to an extent “greater than any official report would indicate,” the team 
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recommended a long-term investigation and in 1925 the Rockefeller Foundation established the 
West African Yellow Fever Commission and began construction on an extensive laboratory near 
Lagos, Nigeria.
2
 The commission’s primary objective was to eradicate yellow fever from the 
West African coast through the mosquito control measures that had been successfully deployed 
in the Americas. It was therefore necessary to first confirm that yellow fever in West Africa was 
the same disease and that it was transmitted by the same mosquito vector, the Aedes aegypti 
mosquito. At the time it was thought that yellow fever was caused by a bacteria, but when the 
bacteriologists in Lagos failed to isolate the bacteria in question they began to doubt whether 
yellow fever in the Americas was in fact the same disease found in the African context. Then in 
1927 researchers at the Pasteur Institute in Dakar and the Rockefeller team working in West 
Africa isolated a virus that was later verified as the causal agent of yellow fever on both sides of 
the Atlantic. This discovery figures prominently in the historical literature not only because it 
was the first flavivirus to be identified but because in 1931 the Asibi virus strain that the 
Rockefeller team isolated from a man named Asibi became the basis of what remains to this day 
one of our most effective and efficient vaccines—conferring what is now thought to be a life-
time immunity to yellow fever in between 95 and 99 percent of those who receive the vaccine.
3
  
 The development of an effective preventive vaccine could not have come at a more 
fortuitous moment. In the early 1930s experts in Brazil found evidence that yellow fever was not 
simply an “urban” disease transmitted during epidemic outbreaks between human hosts by Aedes 
aegypti mosquitoes but that it also existed in an endemic form among primates. Sylvatic or 
“jungle” yellow fever, as the endemic form became known, had a more complex transmission 
cycle involving many different mosquito vectors and animal hosts and this was later found to be 
especially true in Africa. Serving as a permanent reservoir of disease and potential re-infection of 
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human populations and urban centers, endemic yellow fever meant that eradication would never 
be possible. Thus just as even the most ardent advocates of yellow fever eradication had to admit 
defeat, effective vaccines came on line to make complete eradication far less necessary. In a 
historiography of yellow fever that has almost exclusively focused on the Americas and to a 
lesser extent on narratives of eradication, the discovery of sylvatic yellow fever and the 
development of the vaccine tends to be the end of the story.
4
 The mass vaccination campaigns 
that began in in Brazil in 1937 combined with targeted mosquito control measures put an end to 
the yellow fever epidemics that had once wreaked havoc across much of the “New World.”5 Yet 
in many ways, in the African context, this is just the beginning of the story. For while 
Rockefeller’s West African Yellow Fever Commission did eventually pack its bags and leave 
Nigeria in 1934, the decision to abandon eradication in West Africa had been made before the 
discovery of sylvatic yellow fever in Brazil. In fact, the commission had planned to complete 
their work and leave Nigeria by the end of 1931. Citing inadequate sanitation as well as 
demographic and cultural factors, the commission report explained that, “the time was not yet 
ripe for the development of radical campaigns looking toward eradication of yellow fever in 
West Africa.”6  
As eradication appeared less and less feasible in West Africa, the commission began 
instead to study yellow fever immunity. Testing people for acquired yellow fever immunity 
sought to map the reach of yellow fever in Africa and around the world. With the expansion of 
commercial air travel, these “immunity surveys” were an essential means of preventing the 
global spread of yellow fever. Of special concern were the vast non-immune populations of Asia, 
where Aedes aegypti mosquitoes were found but, as immunity surveys confirmed, remained free 
from yellow fever. Air travel significantly raised the risk of infected travelers and mosquitoes 
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spreading the virus faster and further than ever before. Instituting precautionary measures 
required mapping the reach of endemic yellow fever.
7
 After discovering that monkeys were 
susceptible to the disease and could be used in laboratory experiments, the West African Yellow 
Fever Commission developed what were called “protection tests.” These tests involved injecting 
a previously unexposed monkey with both the virus and a human blood sample. A monkey that 
survived was “protected” by the immune bodies present in the person’s blood, indicating that the 
individual had been exposed to yellow fever and lived in what was then deemed an endemic 
zone. If the monkey developed yellow fever, the blood did not appear to provide protective 
immunity indicating that the individual had not come into contact with the virus.
8
 Performing 
protection tests on children as well as adults acted as a ‘timestamp’ providing evidence of when 
yellow fever had last visited a region. As each blood sample had to be tested on at least two 
monkeys in order to ensure accuracy, the initial immunity studies were expensive and time-
consuming. The development of a mouse protection test in 1930 made more extensive 
examinations of immunity possible and in the early 1930s the Rockefeller Foundation agreed to 
devote substantial resources toward the delineation of endemic yellow fever across the globe.
9
 
Immunity surveys thus became the primary endeavor of the West African Yellow Fever 
Commission prior to its departure in 1934.
10
  
Then in December 1935 a man died four days after admission in a Sudanese Hospital and 
all indications strongly suggested that he had been infected with yellow fever. This and other 
apparent clinical cases corroborated immunity surveys of Southern Sudan and Uganda which 
suggested yellow fever was not confined to West Africa as previously thought.
11
 In cooperation 
with the British colonial administration, the Rockefeller Foundation’s International Health 
Division created in 1936 a Yellow Fever Research Institute in Uganda (in the laboratory of the 
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former Human Trypanosomiasis Institute in Entebbe) in order to continue the immunity surveys 
throughout East and Central Africa and to investigate the epidemiology of yellow fever in this 
region of the continent. Needless to say Uganda, like Nigeria, became one of the most closely 
surveyed regions of the world, with blood samples tested for immunity in every region of the 
British Protectorate and in many cases this was done repeatedly. Between 1939 and 1946 a total 
of 15,834 blood samples were tested for immunity at the Institute’s laboratory in Entebbe, 
Uganda and nearly 6,000 of them were from Uganda alone. In addition to identifying a number 
of previously unknown viruses including the now famous West Nile Virus, these immunity 
surveys confirmed the presence of yellow fever across East, West and Central Africa, allowing 
researchers to map what we now call the “African Yellow Fever Belt.” According to the World 
Health Organization it is a region encompassing over 30 countries and affecting approximately 
508 million people, spanning from the Sahel in the north to Angola in the South.
12
 Moreover, 
because nearly half of the blood samples were taken from young children these immunity 
surveys indicated the recent presence of yellow fever in many regions of the continent.  
From the evidence surrounding the protection tests and the debates over how to ensure 
the safety of air travel it is absolutely clear that the immunity surveys were a means of mapping 
endemic regions in order to shield vulnerable populations outside endemic zones. The historian 
Heather Bell, who has written one of the few published works on the history of yellow fever in 
Africa emphasizes this point in her chapter on yellow fever in the Sudan. Airports were made 
safe in part by forcing people living nearby to relocate and travelers to endemic regions received 
immunization. In the wake of an epidemic outbreak in the Nuba Mountains, quarantines 
prevented the spread of yellow fever to other parts of the Sudan and those entering or 
transporting goods through the quarantined region were given protective vaccines.
13
 Thus it 
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appears that yellow fever research in Africa largely benefitted non-African populations. Yet the 
archival records of these immunity surveys suggest a more complicated picture. Even within 
highly endemic regions of the continent, regions where immunity surveys routinely identified 
individuals whose blood samples provided immunity to yellow fever, the vast majority of those 
tested did not appear to have immunity. Despite a few exceptions and at least one major caveat, 
preliminary analysis of the records indicate that the vast majority of people living within the 
endemic regions of the continent tested as non-immune.  
Thus, for example, the West African Yellow Fever Commission’s final report found that 
at least 50 percent of the people appeared to be protected from yellow fever in only 23 of the 149 
the towns where blood samples were taken –in other words, in only 15 percent of the surveyed 
regions did at least half of those tested appear to have immunity to yellow fever. In 85 percent of 
the towns or 126 of the 149 surveyed at least 70 percent of the people did not appear to have 
immunity to yellow fever (and this figure notably excludes towns where 30 or more percent of 
the adults showed immunity but the children sampled did not). In many cases the percentage of 
people who had acquired immunity appears to have been far lower, as in Accra where only 8 
percent showed immunity or Freetown where 22 percent of the adults but only 3 percent of the 
children had immunity or parts of the former Belgian Congo which also indicated immunity 
protection ranging from 0 to 19 percent in all but one case.
14
 In East Africa where the very 
presence of yellow fever immunity came as a shock to many, the fact that the vast majority of the 
people had not acquired immunity to yellow fever is perhaps less noteworthy. Yet if this 
evidence is read as not only a map of endemic zones but also as an accounting of populations at 
risk for yellow fever infection the extent to which people within the “African Yellow Fever Belt” 
exhibited no immunity is of particular consequence. Taken in aggregate less than 9 percent of the 
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population in Uganda tested positive for acquired immunity to yellow fever, less than 12 percent 
of the Congo samples tested in East Africa, less than 10 percent of those from Zambia and less 
than 20 percent of the Sudanese. For Egypt, Eritrea, Somalia, Ethiopia, Kenya, Tanzania, 
present-day Malawi and Mozambique fewer than 5 percent appeared to be immune and in many 
of these territories the actual results indicated that less than 1 percent of the population may have 
been protected.
15
  
The most important caveat that must be noted is that these protection tests were without 
question not sensitive enough to consider definitive.
16
 More investigation is needed in order to 
establish how sensitive they may have been. What is more, the test itself erred on the side of 
caution when it came to reporting false positives. Thus the percentages cited above are certainly 
low and it is difficult to speculate about how much higher they might have been. Yet an expert 
on yellow fever in Africa, Thomas P. Monath, has cited more recent blood tests which indicate 
that the annual incidence of endemic yellow fever in Africa is approximately 1 percent, a figure 
suggesting that in the absence of large-scale epidemic outbreaks (or vaccination) acquired 
immunity and protection from yellow fever within endemic regions may have been quite low.
17
 
Certainly the immunity surveys conducted to map endemic yellow fever suggested that 
significant numbers of people living within the “African Yellow Fever Belt” may not have 
acquired immunity to the disease.   
 
Preventive Vaccines and Vaccination in Africa 
With yellow fever eradication off the table, the only viable recourse was to provide 
vaccines. In the French colonial territories vaccination began as early as June of 1934, using a 
vaccine developed by the Pasteur Institute in Dakar that became known as the “Dakar scratch 
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vaccine” because it was administered by simply scratching the vaccine under the skin. Beginning 
in 1940 this vaccine became the basis of widespread compulsory campaign in which 50 million 
doses were reportedly administered throughout the French colonial territories by 1960. In the 
early years of yellow fever vaccine development it was not known how long the immunity 
provided by the vaccine would last and so French authorities initially planned to administer the 
vaccine throughout their African colonial territories every 4 years. Yet, by 1950 they could no 
longer ignore reports of dangerous side-affects and in particular the development of encephalitis 
in children under the age of ten, resulting in numerous deaths. Although they stopped using the 
vaccine to immunize European children in 1951, it was not until 1960 that the same policy was 
applied to African children and production of the “Dakar scratch vaccine” continued surprisingly 
until 1982.
18
 
Unfortunately the colonial subjects within the British African territories did not 
ultimately fare much better. Initially however the widespread use of vaccines in Anglophone 
Africa looked quite promising. In addition to continuing their immunity surveys, the Rockefeller 
Yellow Fever Institute in Uganda and in Nigeria after it reopened in 1944, focused a great deal 
on vaccination. Research questions that remained paramount included the safety of the 
Rockefeller vaccine, known as 17D, how long it took before the vaccine provided immunity and 
how long the immunity remained in effect. In Nigeria, researchers also tried in vain to develop a 
“scratch” version of 17D, as the scratch technique had many practical advantages.19 Yet they did 
not adopt the French vaccine because even in the 1930s and 1940s there appear to have been 
questions about its safety and while 17D did initially encounter safety concerns, they were fairly 
rapidly addressed (and the more recent adverse cases that have been reported are exceptionally 
rare--1 in 200,000/250,000 for viscerotropic events resembling wild-type yellow fever and .3-.5 
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per 100,000 for neurotropic disease).
20
 When I began this project I expected the refrigeration 
requirements of 17D to be the limiting factor, as the vaccine must be kept within a cold-chain to 
remain viable. And while ultimately the added costs thereby associated with 17D may have 
influenced the British decision to only provide yellow fever vaccines in the wake of an already 
emerging epidemic, this was not initially the case.  
Despite the well-known refrigeration requirements of 17D, discussions about the 
development of a program to provide the vaccine on a widespread scale were already underway 
in the late 1930s as it was acknowledged that vaccination was a more cost-effective preventive 
measure than mosquito control.
21
 Moreover, Rockefeller researchers involved in the immunity 
surveys recommended the implementation of both mosquito control and vaccination. When 
immunity surveys in 1942 indicated the presence of yellow fever in Eritrea, for instance, the 
experts at the Yellow Fever Research Institute in Uganda argued that, “In view of the fact that it 
will necessarily take considerable time to effectively control domestic mosquito breeding in 
Massawa the question of a mass vaccination of the population should be considered. This is a 
measure which could be carried out quickly and which would provide adequate protection during 
the time required to bring the mosquito vector under control.”22  
Nor were they simply being optimistic about the feasibility and efficacy of mass 
vaccination. Rather during the Second World War authorities met in Nairobi and Khartoum and 
decided to provide yellow fever vaccines “for all military personnel serving in Africa.” The 
Rockefeller Foundation then provided the vaccine produced in its laboratories in New York as a 
contribution to the war effort and the Institute in Uganda “became a testing and distribution 
center for the whole of Africa east of Nigeria, and for the Middle East.” The aim was to ensure 
that yellow fever did not “interfere with the war effort” or inadvertently spread to India and other 
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regions of the East. As part of preventing the global spread of yellow fever, “comprehensive 
programs of vaccination were undertaken in Eritrea and the coastal area of Kenya. 
Approximately 34,000 persons were inoculated in Eritrea by” the Institute’s staff and after 
visiting the Institute for a week, a Dr. Philip oversaw the Kenyan vaccination of approximately 
335,000 people. Thus although much of the over 3 million doses of vaccine distributed from 
Uganda between 1941 and 1945 were for military personnel, it was widely acknowledged that an 
unknown but significant segment of the civilian population received immunizations during the 
war –including police, hospital and railway workers and others involved in transportation. In 
Uganda the Asian population received vaccines, as did the Italian, Polish and other refugees and 
prisoners of war that were stationed in East Africa. Moreover, it was reported that despite this 
mass vaccination effort during the war, “no shipment of vaccine was ever lost, nor even 
sufficiently delayed in transit to render it unsuitable for use.”23  
 What is more, an epidemic outbreak in western Uganda in 1941 led to what may have 
been the first mass vaccination campaign benefitting civilian populations in the British colonial 
territories. The epidemic occurred in Bwamba county where the Yellow Fever Research Institute 
established a field station in order to study the epidemiology of the disease on the edge of the 
Bwamba forest. The epidemic was discovered through repeated protection tests in which 48 
people who had been non-immune according to tests performed in 1939, tested positive for 
yellow fever immunity in April and June of 1941. Thus although clinical cases were not 
forthcoming, this sharp increase in positive protection tests could only mean that an epidemic 
was underway and together with the colonial medical authorities, the Rockefeller staff 
immediately began a mass vaccination campaign. From June to August of 1941 they provided 
yellow fever vaccines to approximately 145,000 people in a fairly remote region of western 
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Uganda, bordering the present-day Democratic Republic of Congo.
24
 In order to prevent the 
spread of the epidemic, the first to be inoculated were people residing in the surrounding territory 
of Toro. By the end of the campaign, vaccine had also been administered to the residents of 
Bwamba county who were at the center of the epidemic itself. The researchers at the Uganda 
Research Institute saw the provision of the vaccine as a major success and attributed the fact that 
the epidemic did not impact neighboring regions to their efforts.  
In 1945, the Wellcome Institute in London and the South African Institute for Medical 
Research in Durban began production of 17D. The plan was for the Wellcome to supply the 
vaccine in Britain and the British West African territories and for the South African Institute to 
provide the vaccine for East and Central Africa. The archives held at the Rockefeller Archive 
Center suggest that in the immediate post-war period the aim was to provide vaccine on a 
massive scale as a preventive measure. In the end, this was not to be. Instead, the British decided 
on a policy of providing yellow fever vaccines only on a very limited scale and only in the wake 
of an already emerging epidemic, as in the case of the epidemic in Bwamba. Whether or not 
Bwamba was seen as a successful model, this then became the practice across most of the 
“African Yellow Fever Belt” in the post-independence period as newly independent countries 
began to shoulder the economic burden of public health expenditure. When the neo-liberal fiscal 
policies of structural adjustment later took an even greater toll on health spending, yellow fever 
vaccination coverage across much of the sub-continent was further undermined.  
 
Conclusion                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   
Thus although a relatively safe and highly effective vaccine has been available for over 
75 years, the African people living with the greatest risk of yellow fever infection historically 
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had very little if any access to this life-saving preventive measure. It appears that the only 
vaccine made available to African people on a widespread basis had such dangerous side-effects 
that, although effective in preventing yellow fever outbreaks, it has not been in production for 
over three decades. The consequences are not difficult to discern. While yellow fever epidemics 
came to a standstill in the French colonial territories during the period coinciding with the 
compulsory vaccination campaign using the “Dakar scratch vaccine,” outbreaks continued 
unabated in neighboring British colonial territories including notably present-day Nigeria, Ghana 
and the Gambia. Illustrating the public health risks facing non-immune populations living in 
endemic zones, one of the worst epidemics in recent times occurred in Ethiopia between 1960 
and 1962 with over 100,000 cases and an estimated 30,000 deaths. Although yellow fever 
incidence in Africa is by some accounts significantly underreported (and according to some 
estimates is 10 to 500 times higher), there has been a pronounced upsurge in yellow fever since 
the early 1980s, which most observers attribute to a further breakdown in yellow fever vaccine 
coverage coinciding with the economic crisis and subsequent cuts in medical provision across 
the continent.
25
 Nigeria again stands out with a reported 120,000 cases and 24,000 deaths.
26
 And 
while most epidemics have been concentrated in West Africa over the past twenty years, there 
have also been outbreaks in Kenya and southern Sudan and overall incidence has been steadily 
on the rise.
27
 
The World Health Organization estimates that over 90 percent of yellow fever cases 
occur in Africa. This was notably not always the case. From 1950 to 1959 an average of 36 cases 
were reported annually from Africa as compared to 292 annual cases in the Americas, during the 
same time period. Putting aside the problem of underreporting, this suggests that the burden of 
disease has shifted significantly from a time when yellow fever had an impact in the Americas 
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that was comparable if not greater than in Africa to one in which yellow fever has become 
largely an “African disease.” Moreover, since mid-century the Americas have been almost 
entirely free from epidemic outbreaks with yellow fever incidence confined to the “jungle” or 
sylvatic transmission cycles occurring predominantly among people working in forested regions. 
The last “urban” outbreak in the Americas reportedly occurred in Brazil in 1942.28 Due to 
mosquito control programs, which were often tied to or contingent on adequate water supplies, 
and mass vaccination campaigns, yellow fever incidence was significantly reduced in the 
Americas. Despite their proven efficacy these same measures have not been implemented in 
Africa. When we think then of Africa’s high burden of disease, at least in the case of yellow 
fever, we must keep in mind that this was neither natural nor inevitable. Rather it is the result of 
decisions denying African people access to preventive medical care.  
Finally, and on a more positive note, in the first year of the new millennia the Global 
Alliance for Vaccines and Immunization or GAVI began to fund a program to include the yellow 
fever vaccine in the Expanded Programme of Immunization (EPI) for children in Africa, as had 
been the official (WHO) recommendation since 1988. After five years, the very low vaccine 
coverage in Africa began improving with 22 of the 33 countries within the yellow fever belt 
adopting a policy for yellow fever immunization and three reaching the coverage levels required 
to avoid epidemic outbreaks.
29
 A recent analysis of vaccine coverage in Ghana, for instance, 
found that 85 percent of the children within the survey received the yellow fever vaccine.
30
 Yet 
the significant lapse in the provision of yellow fever vaccines in Africa left the bulk of the 
population in many endemic regions without protection and simply integrating the vaccine into 
routine childhood vaccination programs would not prevent epidemics for years to come. As a 
result, a Yellow Fever Initiative began in 2005 as a partnership between WHO, UNICEF, GAVI 
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and the respective ministries of health in order to launch a “catch-up immunization” campaign 
across West Africa. Between 2006 and 2012 approximately 69 million people in 13 countries 
received the yellow fever vaccine, and in 2013 GAVI devoted additional funds for the 
continuation of the initiative and vaccination programs begun in Nigeria and Ethiopia –although 
the Ethiopian campaign is an emergency mass-vaccination following six confirmed cases of 
yellow fever in May of 2013.
31
 If these efforts continue it is possible that, as in the Americas, 
major yellow fever epidemics in Africa may become a thing of the past, perhaps even without 
mosquito control and expanded provision of water and sanitation. To sustain the promise of this 
initiative requires funding for ongoing childhood immunization in Africa. The alternative is, 
however, far more costly both in terms of the lives unnecessarily lost to yellow fever and in the 
far higher cost of emergency immunization. According to one analysis, providing immunization 
in the wake of an already emerging epidemic is not only far less effective but costs over $7 
versus the 65 cents per vaccine it is estimated to cost (in 1991 currency) to incorporate yellow 
fever into routine childhood immunization programs.
32
 Perhaps in the not too distant future 
Africa will no longer bear an unequal burden of this one highly fatal but easily preventable 
disease.  
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